Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Advertisement
Articles by Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Advertisement
Latest Updated Articles
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and LeukemiaDecember 15th 2025
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AMLDecember 7th 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5